Fig. 6

SNORA37 facilitates CMTR1-ELAVL1 interplay in alternative splicing of CD44. a Western blot assay showing the expression of CMTR1 and ELAVL1 in MKN-45 and AGS cells stably transfected with empty vector (mock), SNORA37, scramble shRNA (sh-Scb), sh-SNORA37 #1, or sh-SNORA37 #2. b Co-IP and western blot assays indicating the interaction of CMTR1 with ELAVL1 in AGS cells stably transfected with sh-Scb, sh-SNORA37 #1, or sh-SNORA37 #2. c BiFC assay showing the interaction between CMTR1 and ELAVL1 (arrowheads) within HGC-27 cells co-transfected with pBiFC-VN173-CMTR1 and pBiFC-VC155-ELAVL1, and those stably transfected with sh-Scb or sh-SNORA37 #1, with nuclei staining by DAPI. d Western blot assay indicating the expression of CMTR1 or ELAVL1 in subcellular fractions of MKN-45 and AGS cells stably transfected with mock, SNORA37, sh-Scb, sh-SNORA37 #1, or sh-SNORA37 #2. e Western blot assay showing the levels of CMTR1 and ELAVL1 in subcellular fractions of AGS cells stably transfected with sh-Scb or sh-SNORA37 #1, and those co-transfected with mock or CMTR1. f Cross-linking RIP assay indicating the interaction of ELAVL1 with CD44 pre-mRNA containing alternative splicing sites around exon 10 in AGS cells stably transfected with sh-Scb or sh-SNORA37 #1, and those co-transfected with mock or CMTR1. g and h RT-PCR (g) and western blot (h) assays showing the alternative splicing and expression of CD44v6 and CD44s in AGS cells stably transfected with sh-Scb or sh-SNORA37 #1, and those co-transfected with mock, CMTR1, or ELAVL1. Data are shown as representative of three independent experiments in a-h